Nanochon is building Chondrograft™, a patented implant designed to restore articular cartilage in the knee while allowing immediate weight-bearing and motion. The technology targets young, active patients who have failed conservative therapies and currently face costly, invasive, and often short-lived treatment options. The company is about to launch a 10-patient, phase-I first-in-human clinical study in Canada to assess Chondrograft’s safety and efficacy, and is already planning a larger North American pivotal trial aimed at eventual FDA clearance. Beyond the implant, Nanochon has partnered with ProVoyance to create an MRI-based pre-operative surgical-planning software platform. The newly raised capital will also accelerate manufacturing capabilities and deepen R&D. Including the latest round, Nanochon has secured a total of $11.3 million in funding to date, underscoring strong investor confidence in its approach.

Total raised

$8M

Funding rounds

2

Latest round

Seed

Latest activity

Jan 2026